Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Second solid cancers after allogeneic hematopoietic stem cell transplantation.

Genevieve Gallagher1, Donna L Forrest

  • 1Leukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, British Columbia Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada.

Cancer
|November 30, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual Targeting of Smoothened, a Key Regulator in the Hedgehog Pathway, and BCR-ABL1 Effectively Eradicates Drug-Insensitive Stem/Progenitor Cells in Chronic Myeloid Leukemia.

Cells·2025
Same author

Racial Disparity in Myeloablative Hematopoietic Cell Transplantation Outcomes in Patients with Hematological Malignancies Older Than 45 Years.

Blood cell therapy·2025
Same author

Identification of a PAK6-Mediated MDM2/p21 Axis That Modulates Survival and Cell Cycle Control of Drug-Resistant Stem/Progenitor Cells in Chronic Myeloid Leukemia.

International journal of molecular sciences·2025
Same author

Outcomes Following Second Allogeneic Stem Cell Transplant for Graft Failure or Poor Graft Function: A Single Centre Experience.

Stem cell reviews and reports·2025
Same author

Determining the best premedication regimen to prevent rabbit anti-human thymocyte globulin infusion-associated reactions: A retrospective study comparing two hematopoietic stem cell transplant centers.

Transplant immunology·2025
Same author

Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study.

Leukemia & lymphoma·2024
Same journal

Toward exercise as standard care for older cancer survivors.

Cancer·2026
Same journal

Maintenance therapy in gynecologic malignancies: Current and future state.

Cancer·2026
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
Same journal

Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

Cancer·2026
See all related articles

Patients undergoing allogeneic stem cell transplant have a higher risk of developing second cancers. Advanced age and a female donor increase this risk, warranting further investigation.

Area of Science:

  • Hematology
  • Oncology
  • Transplant Medicine

Background:

  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a life-saving procedure.
  • Understanding the long-term risks, including secondary malignancies, is crucial for patient care.

Purpose of the Study:

  • To determine the incidence of second solid cancers after allo-HSCT.
  • To identify risk factors associated with the development of these cancers.

Main Methods:

  • Retrospective review of 926 patients who underwent allo-HSCT between 1985 and 2003.
  • Statistical analysis including risk ratio and multivariate analysis to identify significant risk factors.

Main Results:

  • A 10-year cumulative incidence of 3.1% for all solid tumors was observed.

Related Experiment Videos

  • Patients had a 1.85-fold increased risk of developing a second solid cancer compared to the general population.
  • Recipient age over 40 and a female donor were significantly associated with increased risk.

    • Conclusions:

    • Patients undergoing allo-HSCT face an elevated risk of second solid cancers.
    • Advanced recipient age at transplant is a key risk factor.
    • An unexpected increased risk was observed in patients receiving grafts from female donors.